# Shattuck Labs (STTK) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/STTK
## Company Profile
- Ticker: STTK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Biologics, Oncology, Immunology
## Stock Data
- Close: 7.18 USD
- Market cap: 373434117.79 USD
- Last updated: 2026-08-11
## Business Overview
### Immune-Mediated Diseases
Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells.
### SL-325
SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and multiple-ascending-dose study and is being prepared for Phase 2 development in Crohn's disease.
### DR3 Platform
Shattuck is also exploring bispecific DR3-blocking antibodies and additional indications where excessive DR3 signaling may contribute to chronic inflammation.
## Why The Stock Is Moving

As of Aug 11, 2026, STTK closed up 0.56% at $7.18. No new same-company headline was identified in the current news window.

## Future Catalysts

- Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
- Initiation of a Phase 2 study of SL-325 in Crohn's disease in the third quarter of 2026.

## Recent News
- 2026-06-10 04:21 EST — [Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-pricing-of-75-million-public-offering-1147ed04) — Source: Shattuck Labs
- 2026-06-09 20:18 EST — [Shattuck Labs, Inc. Announces Proposed Public Offering](https://biopharmsignal.com/news/STTK/shattuck-labs-inc-announces-proposed-public-offering-81c3c0e1) — Source: Shattuck Labs
- 2026-06-09 12:00 EST — [Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-exercise-of-outstanding-common-stock-warrants-and-provid-5897ec16) — Source: Shattuck Labs
- 2026-06-08 10:00 EST — [Shattuck Labs Announces Phase 1 Results for SL-325](https://biopharmsignal.com/news/STTK/shattuck-labs-announces-phase-1-results-for-sl-325-e7f7caf7) — Source: Shattuck Labs
- 2026-06-05 20:05 EST — [Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8](https://biopharmsignal.com/news/STTK/shattuck-labs-to-host-investor-call-and-webcast-on-phase-1-clinical-data-of-sl-3-d25fd1ba) — Source: Shattuck Labs